Opendata, web and dolomites

UCRxF

A novel ulcerative colitis treatment - A phase III ready feasibility study

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 UCRxF project word cloud

Explore the words cloud of the UCRxF project. It provides you a very rough idea of what is the project "UCRxF" about.

strategy    primary    upfront    fast    line    revenues    innovative    patients    tested    royalties    reinvested    colitis    finance    initiation    license    milestone    sales    q4    approved    2018    caused    business    institutet    generate    immunological    payments    compounds    drug    preparations    pharmaceutical    reported    toxicology    diseases    index    disease    continue    mechanism    purpose    attractiveness    efficient    profile    treat    prior    active    cure    karolinska    ulcerative    company    severe    unmet    licensing    ab    pharmaceuticals    debilitating    medical    uc    platform    additional    sweden    immunomodulatory    clinical    demonstrated    asset    moderate    science    offers    dna    feasibility    preparation    portfolio    action    colon    companies    party    drugs    dims    international    ready    larger    cobitolimod    park    manufacturing    inflammation    broad    safety    planning    efficacy    commercial    biological    iib    deal    sequences    treatment    medication    partnering    stockholm    acute    chronic   

Project "UCRxF" data sheet

The following table provides information about the project.

Coordinator
INDEX PHARMACEUTICALS AB 

Organization address
address: TOMTEBODAVAGEN 23A
city: STOCKHOLM
postcode: 171 77
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.indexpharma.com/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INDEX PHARMACEUTICALS AB SE (STOCKHOLM) coordinator 50˙000.00

Map

 Project objective

InDex Pharmaceuticals AB is a pharmaceutical development company based at the Karolinska Institutet Science Park in Stockholm, Sweden. The company´s primary asset is cobitolimod, which is in late phase clinical development as a new medication to treat moderate to severe active ulcerative colitis (UC); a chronic, debilitating disease with a high unmet medical need. UC is caused by chronic inflammation of the colon, and there is no cure.

Cobitolimod offers a novel and unique mechanism of action for the treatment of UC, and has demonstrated a higher efficacy and better safety profile in clinical studies than what has been reported for currently approved biological drugs. Cobitolimod is part of the broad InDex portfolio of DNA-based ImmunoModulatory Sequences (referred to as DIMS), which have the potential for treatment of various immunological diseases. Cobitolimod is currently being tested in a phase IIb clinical study with top line results expected in Q4 2018.

InDex’s business strategy is to out-license cobitolimod to a larger international pharmaceutical company prior to the initiation of clinical phase III development. This will generate revenues for InDex from upfront and milestone payments as well as royalties from third party sales, which can then be reinvested in the company to finance development of new compounds from the DIMS technology platform.

For clinical phase III, additional manufacturing and toxicology work as well as commercial preparations are essential. The planning and preparation of this work is the purpose of this feasibility study, which is a crucial part of the cobitolimod phase III ready programme, increasing the attractiveness of the asset in partnering discussions with pharmaceutical companies looking for innovative new products. A licensing deal will ensure that the development of this promising, innovative drug will continue in a fast and efficient way to reach patients with this debilitating disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UCRXF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UCRXF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More